huMAb OX40L

OX40L-targeting monoclonal antibody · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for huMAb OX40L, covering 2016-08-02 to 2016-08-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma [Phase 2]

See pricing